GPVI is a 62 kDa membrane glycoprotein expressed in non-covalent association with the Fc receptor γ chain on human and murine platelets, and serves as the major activating receptor for collagen. GPVI-specific antibodies have the capacity to specifically deplete GPVI from mouse and human platelets in vivo, rendering them unresponsive to collagen and GPVI-specific agonists. Such antibodies do not remove GPVI from non-circulating platelets in vitro, however, making it difficult to evaluate their anti-thrombotic potential and mechanism of action, particularly in human platelets. We devised a model system in which human platelets are introduced into the retro-orbital plexus of NOD/SCID mice, allowed to circulate, and evaluated for the effects of GPVI-specific murine monoclonal antibodies (mAbs) on platelet survival and function. GPVI-specific mAbs triggered depletion of GPVI from human, but not murine, platelets. Soluble truncated human GPVI appeared concomitantly in mouse plasma. GPVI-depleted human platelets had markedly diminished responses to GPVI-specific agonists, and unexpectedly exhibited somewhat depressed responses to G-protein-coupled agonists. The ability to evaluate in living mice the in vivo function and survival of circulating human platelets may prove valuable for determining mechanisms of antibody-mediated platelet passivation, and aid in the development of novel anti-platelet therapeutics.
Introduction
An array of agonist receptors reside on the surface of platelets that, upon exposure to ligands, initiate the activation of a complex network of signaling pathways leading to platelet activation, adhesion and thrombus formation. Collagen, a major component of the extracellular matrix, acts as an important primary indicator to the presence of vessel injury. GPVI, the principal platelet collagen receptor, is a 62 kDa platelet membrane glycoprotein expressed on the surface of human and murine platelets in a non-covalent complex with the immunoreceptor tyrosine-based activation motif (ITAM)-containing subunit, the FcRγ chain 1;2 . GPVI is a member of the immunoglobulin gene (Ig) superfamily that is composed of two extracellular Ig-homology domains, a transmembrane domain, and a 51-amino acid cytoplasmic domain [3] [4] [5] . The GPVI/FcRγ chain complex serves as the major platelet activating receptor for collagen and signals via the Syk/SLP-76/PLCγ2 pathway to activate the integrins α 2 β 1 and α IIb β 3 (also known as GPIIb-IIIa), leading to platelet activation and thrombus formation 6;7 .
Recent studies by Nieswandt and colleagues have shown the injection into mice of rat anti-mouse GPVI monoclonal antibodies (termed JAQs 1, 2, and 3) results in specific, long-term immunodepletion of GPVI from the surface of circulating murine platelets [8] [9] [10] . Platelets isolated from mice treated in this manner exhibit a corresponding loss of responsiveness to collagen and the GPVI-specific agonist, collagen-related peptide (CRP) 8;9 . Antibody-mediated depletion of GPVI appears to be operable in humans as well, as platelets from a patient with a circulating autoantibody specific for GPVI, like the platelets from JAQ-1-treated mice, are devoid of cell surface GPVI, fail to
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The ability of anti-GPVI antibodies to render platelets unresponsive to collagen suggests that such reagents, especially if non-activating, might have therapeutic benefit in reducing mural thrombosis in a variety of clinical settings. Attempts to examine the efficiency with which GPVI-specific mAbs are able to passivate human platelets have unfortunately been compromised by the observation that most are unable to effect depletion of GPVI ex vivo (refs. 8;10 , and Boylan and Newman, unpublished observations July 2004). Delineating the molecular mechanisms underlying GPVI immunodepletion in circulating human platelets has been similarly confounded. While early studies suggested that rat anti-mouse GPVI mAbs initiate internalization of antibody/murine GPVI complexes 8 , a number of recent in vitro studies suggest that agents that cause mitochondrial damage 12 or activate platelets after binding GPVI 13;14 are able to activate one or more yet-to-be-identified matrix metalloproteinases (MMPs) that proteolytically cleave the extracellular domain of GPVI, in some cases releasing the extracellular domain of GPIbα as well 12;15 .
To examine the ability of anti-GPVI mAbs to reduce GPVI expression on human platelets in an activation-independent manner and to dampen GPVI-mediated platelet activation responses, we have developed an in vivo model system in which human platelets are injected into NOD/SCID mice and allowed to circulate for up to two days.
We show that co-injection of monovalent Fab fragments specific for human GPVI, which 
Materials and methods

Antibodies and reagents
11A12 and 6B12 are well-characterized mouse anti-human GPVI-specific monoclonal antibodies (mAbs) that have been previously described 7;16 . The mAbs PECAM-1.3 and 235.1, specific for the extracellular and cytoplasmic domains, respectively, of PECAM-1, have been described 17 . AP2, which recognizes a complexdependent integrin GPIIb-IIIa epitope 18 , was kindly provided by Dr. Robert R.
Montgomery (Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI).
Monovalent Fab fragments of several of the above mAbs were prepared using the Immunopure preparation kit (Pierce Biotechnology, Rockford, IL). The anti-GPVI cytoplasmic tail antibody was raised by immunizing New Zealand White rabbits with a previously-described maltose-binding protein (MBP)-GPVI cytoplasmic tail fusion protein 19 . Serum derived from these rabbits was subjected to sequential affinity chromatography on columns of MBP-GPVI cytoplasmic tail fusion protein and MBP alone coupled to Affi-Gel 10/15 (Bio-Rad Laboratories, Hercules, CA). The fibrinogenmimetic mAb, PAC-1 20 , pre-labeled with fluorescein isothiocyanate (FITC), was purchased from BD Biosciences (San Jose, CA). In some cases, mAbs were directly conjugated to Alexa Fluors 647 (11A12 and AP2) and 488 (AP2) using a kit purchased from Molecular Probes Inc. (Eugene, OR). Collagen-related peptide (CRP) was synthesized and cross-linked as previously described 21;22 .
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Circulation of human platelets in NOD/SCID mice
Human blood drawn into acid-citrate-dextrose and supplemented with prostaglandin E 1 (PGE 1 ) at 50 ng/ml was incubated at room temperature for 10 minutes then spun at 200g for 10 minutes. Platelet rich plasma (PRP) was collected, and PGE 1 was added to 50 ng/ml. Platelets were incubated at room temperature for 10 minutes and then spun at 750g for 10 minutes. The platelets were resuspended in human plasma at 2.0 
Preparation of washed platelets
20-50 μl whole blood was obtained from the mouse tail vein and collected into 1.0 ml of 1:9 mixture of 3.8% sodium citrate/Tyrodes-HEPES buffer containing PGE 1 at 50 ng/ml. 1.0 ml of blood mixture was layered onto 2 ml of Fico/Lite Platelets (Atlanta Biologicals, Norcross, GA) and spun for 15 minutes at 350g. 1.0 ml of the platelet layer was added to 3.0 ml of Tyrodes supplemented with 67 ng/ml PGE 1 . Platelets were washed by centrifugation at 750g for 10 minutes and resuspended in Tyrodes-HEPES buffer.
Platelet activation assays
Washed platelets obtained from mice 24 hours after injection of human platelet concentrates were stimulated with CRP, ADP, thrombin, or a cocktail of 10 units/ml thrombin + 10 μM adenosine diphosphate (ADP) + 100 μM epinephrine and incubated for 20 minutes at room temperature in fluorescein isothiocyanate (FITC) conjugated PAC-1 at 2.5 μg/ml and 1 mM CaCl 2 . Alexa Fluor 647-conjugated AP2 was then added at 5 μg/ml, platelets were incubated for an additional 20 minutes at room temperature and directly analyzed on a BD LSR II (Franklin Lakes, NJ).
Platelet aggregation
Four hundred μl of washed human platelets in Tyrodes-HEPES buffer at 3.0 x 10 8 platelets/mL were added to siliconized glass cuvettes at 37°C with constant stirring at 1000 rpm. CaCl 2 and fibrinogen were added to a final concentration of 1 mM and 300 μg/mL, respectively. Platelet aggregation was measured in a whole-blood lumi-ionized calcium aggregometer (Chrono-Log, Havertown, PA) for 2 minutes in the presence of 10μg/ml of an isotype control mAb or mAb 6B12, and then finally activated with 7 ng/ml CRP.
Immunoprecipitation of GPVI from plasma
Human platelets were introduced into the circulation of NOD/SCID mice as described above. 24 hours after transfusion, mice were lethally anesthetized with tribromo-ethanol administered intraperitoneally. Whole blood was collected from the inferior vena cava into 0.1 vol of 3.8% sodium citrate, incubated at room temperature for 10 min in the For personal use only. on October 31, 2017. by guest www.bloodjournal.org From presence of 50 ng/ml PGE 1 , and then centrifuged at 200g for 10 minutes to remove red blood cells. Following re-addition of 50 ng/ml PGE 1 , the supernatant containing plateletrich plasma was spun 750g for 10 minutes to pellet platelets and remaining leukocytes, and the supernatant subjected to a final spin at 100,000g for 60 min. Soluble GPVI (sGPVI) was immunoprecipitated by nutating 250 μl mouse plasma overnight with 50 μl streptavidin-Sepharose that had been precoated for 12 hours at 4˚C with 0.5 mg/ml biotinylated 11A12, and washed 3X in Tyrone's buffer. Immuno-captured proteins were eluted with 0.1M glycine pH 2.7 for 10 minutes at room temperature and neutralized in 1.5 M TRIS, pH 8.8.
For
Results
Human platelets survive and circulate in NOD/SCID mice
Though GPVI is lost from the platelet surface in vitro following treatment with agents that activate platelets or damage mitochondria, attempts to deplete GPVI under in vitro conditions using mAbs that do not injure or activate platelets have been 
Immunodepletion of GPVI from circulating human platelets using monovalent Fab fragments of the murine GPVI-specific mAb, 6B12
Non-activating, GPVI-specific mAbs that dampen platelet responses to collagen have potential therapeutic applications as anti-thrombotic agents; however, they have not to date been shown to be capable of removing GPVI from the surface of human platelets.
The finding that human platelets can circulate in NOD/SCID mice for more than 24 hours (Figure 1 ) allowed us to investigate the consequences of antibody binding to human GPVI under in vivo conditions. Evidence that the non-function-blocking, GPVI-specific mAb, 6B12, does not activate platelets, even in divalent form, is provided in Figure 2A .
When Fab fragments of 6B12 were introduced into NOD/SCID mice together with ~4 x 10 8 human platelets, approximately 50% of circulating human platelets lost GPVI expression within 24 hours (lower right panel of Figure 2B ). In contrast, Fab fragments
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From specific for PECAM-1 (upper right panel of Figure 2B ) or an isotype control Fab (not shown) had no effect of GPVI surface expression. The ability of monovalent Fab fragments to remove GPVI from the surface of human platelets demonstrates that clustering of the GPVI/FcRγ chain complex is not required for antibody-mediated immunodepletion -a result in keeping with the observations of Nieswandt et al. 8 and
Schulte et al. 10 , who found that rat anti-mouse GPVI Fabs could achieve the same effect in murine platelets in vivo.
6B12 treatment results in loss of GPVI-specific agonist responses as well as diminished responsiveness to agonists for G-protein coupled receptors
To determine whether in vivo introduction of mAb 6B12 could effectively dampen the response of circulating human platelets to GPVI-mediated activation signals, we examined their ability to bind the fibrinogen-mimetic mAb, PAC-1, following exposure to the GPVI-specific agonist, CRP (collagen-related peptide). As shown in Figure 3A , human platelets taken from mice treated with 6B12 Fabs lost almost half of their reactivity to high-dose CRP, as reported by PAC-1 binding, compared with human platelets derived from control mice that had been treated with PECAM 1.3 Fabs.
Somewhat unexpectedly, human platelets taken from 6B12-treated mice also consistently exhibited slightly deceased (~20%) PAC-1 binding upon activation with a cocktail of agonists comprised of 10 U/ml thrombin, 10 μM ADP and 100 μM epinephrine -all of which stimulate G-protein coupled receptors on the platelet surface. To further characterize the nature of this activation defect, more detailed dose-response studies were performed for ADP, thrombin, and CRP. As shown in Figure 3D , PAC-1 binding to
6B12-treated human platelets was markedly reduced at all concentrations of CRP examined, as expected, more or less in proportion to the degree of GPVI depletion effected by the antibody (bottom right panel of Figure 2B ). In contrast, ADP-and thrombin-induced PAC-1 binding to 6B12-treated human platelets was nearly normal at low-dose agonist concentrations, but was reduced by 38% and 43%, respectively, when high concentrations of ADP or thrombin were used.
Thus, it appears that immunodepletion of the GPVI/FcRγ chain complex exerts somewhat more widespread effects on platelet function than had previously been thought.
A soluble, truncated form of human GPVI is shed into mouse plasma as a result of
6B12-induced immunodepletion
Though a number of recent in vitro studies suggest that agents that either cause mitochondrial damage 12 or activate platelets via GPVI 13;14 can lead to platelet-associated metalloproteinase-mediated shedding of GPVI into the extracellular milieu, the mechanism by which non-activating, GPVI-specific mAbs are able to effect GPVI depletion, particularly from the surface of human platelets, still is not known. Since the latter class of reagents is likely to be more clinically useful, and to investigate whether 6B12 treatment caused GPVI shedding in vivo, human platelets were injected into mice in the presence of anti-GPVI or anti-PECAM-1 Fabs and allowed to circulate for 24 hours.
Plasma samples were then collected and subjected to immunoprecipitation using streptavidin-Sepharose beads that had been saturated with biotinylated 11A12 -a murine anti-GPVI mAb that binds an epitope on human GPVI distinct from that for 6B12, and therefore does not compete for binding. Immuno-captured proteins were acid-eluted
from the streptavidin-11A12 beads, subjected to SDS PAGE and Western blotted with 6B12. As shown in Figure 4 , plasma obtained from 6B12-treated (lanes 3), but not PECAM-1.3-treated (lanes 2), mice contained a prominent 50 kDa soluble form of human GPVI that reacted with an antibody to the extracellular, but not cytoplasmic, domain of GPVI, indicating that this fragment is comprised of a truncated, cleaved form of GPVI.
GPVI derived from human platelet lysate (HPL) reacted with both antibodies, as expected. These data are consistent with proteolytic cleavage being, at least in part, responsible for the mechanism by which 6B12 depletes GPVI from the platelet surface.
Discussion
The major findings of the present investigation are that (1) monovalent murine antihuman GPVI Fabs can effectively deplete GPVI from the surface of human platelets in vivo, (2) they appear to act largely by inducing ectodomain shedding, and (3) the NOD/SCID mouse model that we describe herein may be useful for future investigations in which the function and/or survival of circulating human platelets following treatment with various anti-platelet agents needs to be examined.
Immunodepletion of GPVI from the platelet surface was first observed in a murine model that involved injecting mice with rat anti-mouse GPVI mAbs, JAQ1, JAQ2, or JAQ3 [8] [9] [10] . JAQ mAb-treated mice exhibited mild, transient thrombocytopenia, long-term immunodepletion of GPVI, and diminished platelet responsiveness to collagen. More recent studies suggest that antibody-mediated loss of GPVI can also take place on human platelets, as evidenced by a recently-described patient suffering from autoimmune thrombocytopenia caused by an auto-antibody specific for GPVI, concomitant with a loss of platelet responsiveness to GPVI-specific agonists and a mild bleeding diathesis 11 .
That antibody-induced GPVI removal has now been demonstrated in both humans and mice raised the intriguing possibility that antibodies to GPVI might be used as adjunct therapy to temporarily pacify platelets during a thrombotic episode -i.e. myocardial infarction or stroke, during unstable angina, or prior to clinical procedures like percutaneous transluminal coronary angioplasty that are associated with increased incidence of mural thrombus formation. Several obstacles to making further progress in this area, however, exist. First, studies performed in mice using rat anti-mouse GPVI For personal use only. on October 31, 2017. by guest www.bloodjournal.org From reagents of the JAQ series -which by themselves do not activate platelets -have demonstrated that these antibodies immunodeplete GPVI only when administered in vivo -i.e. addition of anti-GPVI mAbs to platelets in vitro has no effect on GPVI surface expression 8 . Second, there currently exists no suitable animal model to evaluate the effectiveness of anti-human GPVI reagents or the consequences of GPVI elimination in human platelets. To circumvent these problems, we undertook the development of a novel NOD/SCID mouse model of GPVI-immunodepletion that employs circulating human platelets in the presence of a mouse anti-GPVI mAb, and used it to begin to address the mechanism of antibody-mediated elimination of GPVI from the human platelet surface.
Human platelets are able to circulate in NOD/SCID mice for more than one day (Figures 1 and 2) , most likely because the immune deficiency of these mice 23 The degree of GPVI elimination achieved in the circulating human platelet-NOD/SCID model is less than that observed by Nieswandt and colleagues for murine platelets using JAQ mAbs [8] [9] [10] . This may due to the fact that GPVI expression on human platelets circulating in NOD/SCID mice has to be determined 18-36 hours following their injection -i.e. before they age and became cleared. In contrast, JAQ-induced depletion of murine platelet surface GPVI has normally been evaluated three or more days following JAQ treatment, and thus may account for the more efficient GPVI immunodepletion observed. The kinetics of human platelet clearance in NOD/SCID mice, therefore, may represent a limitation of this model for examining the effects of antiplatelet agents whose action requires one or more days of systemic exposure.
Nonetheless, the finding that human platelets can circulate and survive in NOD/SCID mice, albeit for a limited period of time, may prove useful for evaluating the in vivo In support of a proteolytic mechanism for GPVI immunodepletion, we found (Figure 4 ) that a readily-detectable, truncated, soluble 50 kDa fragment containing the
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GPVI extracellular, but not cytoplasmic, domain became liberated from human platelets into mouse plasma following in vivo exposure to monovalent Fab fragments of 6B12.
To our knowledge, our observation that non-activating anti-GPVI reagents can induce shedding of the ectodomain of GPVI from the human platelet surface has not been previously demonstrated. Several recent studies, however, have reported GPVI shedding as a consequence of (1) platelet activation following stimulation with a GPVI-specific agonist 13;14 , (2) exposure to an activating GPVI-specific mAb 14 , (3) inhibition of an interaction between calmodulin and the GPVI cytoplasmic domain 13 , or (4) exposure to mitochondrial damaging agents 12;15 . In each of these studies, immunodepletion of GPVI could be attributed to the action of matrix metalloproteinases (MMPs) -a class of enzymes originally characterized by their ability to degrade various elements of the extracellular matrix (for a review, see Mott and Werb 28 ) -because GPVI shedding could be inhibited by the broad range MMP inhibitor, GM6001 [12] [13] [14] . Since MMPs are secreted from α-granules following platelet activation [29] [30] [31] [32] , it is tempting to speculate that calcium mobilization caused by platelet activation induces not only secretion of granuleassociated MMPs, but also concurrent dissociation of calmodulin from the GPVI cytoplasmic tail, resulting in a conformational change in the extracellular domain that exposes a cryptic protease cleavage site and GPVI shedding. In contrast, rat anti-mouse GPVI antibodies 8;10 , patient anti-GPVI autoantibodies 11 , and the mouse anti-human GPVI mAbs used in this study all involve non-activating antibodies that, because they do not cause granule release, may effect GPVI removal via a related protease whose action is facilitated by shear force, or by exposure to other cells that are encountered during circulation. Thus far we have been unable to determine whether activation-independent
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From GPVI shedding in vivo is mediated by an extracellularly-derived MMP-mediated event because most readily-available MMP inhibitors become rapidly inactivated after injection (unpublished observations). We have also attempted to examine whether activationindependent, antibody-induced GPVI shedding might be mediated by the same MMP that cleaves GPIb. If this were true, then GPIb might also be inadvertently clipped when GPVI antibodies are added. Flow cytometric analysis to measure the surface expression of both GPIb and GPV on human platelets taken out of mice treated with mAb 6B12, however, has revealed that GPIb levels are actually increased, not decreased, in the very same platelets in which GPVI has been depleted (B. Boylan and PJ Newman, unpublished observations, November 2005). These data suggest, therefore, either (1) that non-activating anti-GPVI mAbs do not activate the same protease as that responsible for activation-induced GPIb shedding, as recently suggested by Bergmeier et al. 12 or (2) that the protease is the same, but that the 6B12/GPVI/protease complex is not close enough to
GPIb to enable it to be shed. Studies are in progress to identify the source and identity of the responsible GPVI-cleaving protease.
Finally, while GPIIb-IIIa receptor antagonists have been an important addition to the regimen of anti-thrombotics used to reduce the incidence of complications following coronary angioplasty, an undesirable side effect of this class of therapeutics is their propensity, for poorly understood reasons, to cause in ~1% of recipients acute, antibodymediated platelet destruction and/or bleeding 33;34 . Though still a long way from preclinical testing, GPVI-directed therapeutics have the potential to avoid these untoward complications. First, anti-GPVI mAbs, be they rat [8] [9] [10] , human 11 , or mouse (this study) in origin, are rapidly shed from the platelet surface upon binding their target receptor, thereby sparing the platelet from clearance and thus avoiding thrombocytopenia. Second, although platelet reactivity to mural collagen 9 , and perhaps mural laminin 25 For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
